A clinical prediction model for the presence of peripheral arterial disease — the benefit of screening individuals before initiation of measurement of the ankle

Abstract

Measurement of the ankle—brachial index (ABI) can provide important information about the presence of subclinical atherosclerosis. Performing the ABI in the overall population is not feasible, but it can be used in a selected population. A simple prediction rule could be of much use to estimate the risk of an abnormal ABI. This was designed as an observational study in the setting of 955 general practices in The Netherlands. A total of 7454 patients aged ≥ 55 years presenting with at least one vascular risk factor (smoking, hypertension, diabetes, and hypercholesterolemia) and no complaints of intermittent claudication were included. Patients were selected by the general practitioner during visiting hours and from medical records. Main outcome measures included the prevalence of PAD, defined as an ABI below 0.9, which was related to vascular risk factors using regression analyses on which the PREVALENT clinical prediction model was developed. The overall prevalence of PAD was 18.4%. Since the treatment of individuals with a history of coronary heart disease and cerebrovascular disease will not be influenced by the finding of asymptomatic PAD, these individuals were not taken into account for the development of the clinical prediction model. Analyses showed a significantly increased risk for PAD with increasing age, smoking, and hypertension. The clinical prediction model giving risk factor points per factor (age: 1 point per 5 years starting at 55 years; ever smoked: 2 points; currently smoking: 7 points; and hypertension: 3 points), showed a proportional increase of the PAD prevalence with each increasing risk profile (range: 7.0—40.6%). In conclusion, based on the PREVALENT clinical prediction model, the general practitioner is able to identify a high-risk population in which measurement of ABI is useful.

Keywords

ankle—brachial index asymptomatic atherosclerosis peripheral arterial disease screening

References

Dormandy JA , Rutherford RB Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Concensus (TASC). J Vasc Surg 2000; 31: S1—S296.

Hirsch AT , Haskal ZJ , Hertzer NR et al. ACC/AHA guidelines for the management of patients with peripheral arterial diseases (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society for Vascular Medicine and Biology, and the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to develop guidelines for the management of patients with peripheral arterial disease). 2005. American College of Cardiology. URL: http://www.acc.org/clinical/guidelines/pad/index.pdf

Criqui MH , Langer RD , Fronek A. , Feigelson HS , Klauber MR , McCann TJ Mortality over a period of 10 years in patients with peripheral arterial disease . N Engl J Med 1992; 326: 381—86.

Newman AB , Shemanski L. , Manolio TA et al. Ankle—arm index as a predictor of cardiovascular disease and mortality in the Cardiovascular Health Study. The Cardiovascular Health Study Group. Arterioscler Thromb Vasc Biol 1999; 19: 538—45.

Doobay AV , Anand SS Sensitivity and specificity of the ankle—brachial index to predict future cardiovascular outcomes. A systemic review. Arterioscler Thromb Vasc Biol 2005; 25: 1463—69.

Newman AB Peripheral arterial disease: insights from population studies of older adults . J Am Geriatr Soc 2000; 48: 1157—62.

Leng GC , Fowkes FG , Dunbar J. , Housley E. , Ruckley CV Use of ankle brachial pressure index to predict cardiovascular events and death: a cohort study. BMJ 1996; 313: 1440—45.

Mohler ER , Treat-Jacobson D. , Reilly MP et al. Utility and barriers to performance of the ankle—brachial index in primary care practice. Vasc Med 2004 ; 9: 253—60.

Mohler ER Peripheral arterial disease. Identification and implications. Arch Intern Med 2003; 163: 2306—14.

10.

Lijmer JG , Hunink Mgm , van den Dungen Jjam , Loonstra J. , Smit AJ ROC Analysis of noninvasive tests for peripheral arterial disease. Ultrasound Med Biol 1996; 22: 391—98.

11.

Yao Ist. Pressure measurement in vascular disease. In: Bernstein EF (ed). Vascular diagnosis, 4th edition. Mosby-Year Book, 1993: 169—75.

12.

Resnick HE , Lindsay RS , McDermott MM et al. Relationship of high and low ankle brachial index to all-cause and cardiovascular disease mortality: the Strong Heart Study. Circulation 2004; 109: 733—39.

13.

Meijer WT , Hoes AW , Rutgers D. , Bots ML , Hofman A. , Grobbee DE Peripheral arterial disease in the elderly. Arterioscler Thromb Vasc Biol 1998; 18: 185—92.

14.

Stoffers HE , Rinkens PE , Kester AD , Kaiser V. , Knottnerus JA The prevalence of asymptomatic and unrecognized peripheral arterial occlusive disease. Int J Epidemiol 1996; 25: 282—90. 15 Hayoz D. , Bounameaux H. , Canova CR Swiss Atherothrombosis Survey: a field report on the occurence of symptomatic and asymptomatic peripheral arterial disease. J Intern Med 2005; 258: 238—43.

15.

Diehm C. , Lange S. , Darius H. et al, for the getABI Study Group. Association of low ankle brachial index with high mortality in primary care . Eur Heart J 2006; 27: 1743—49.

16.

Newman AB , Siscovick DS , Manolio TA et al. Ankle—arm index as a marker of atherosclerosis in the Cardiovascular Health Study. Cardiovascular Heart Study (CHS) Collaborative Research Group. Circulation 1993; 88: 837—45.

17.

Mackaay Ajc , Beks PJ , Dur Ahm et al. The distribution of peripheral vascular disease in a Dutch Caucasian population: comparison of type II diabetic and non-diabetic subjects. Eur J Vasc Endovasc Surg 1995; 9: 170—75.

18.

Walters DP , Gatling W. , Mullee MA , Hill RD The prevalence, detection, and epidemiological correlates of peripheral vascular disease: a comparison of diabetic and non-diabetic subjects in an English community. Diabet Med 1992; 9: 710—15.

19.

Jonason T. , Bergstrom R. Cessation of smoking in patients with intermittent claudication. Effect on the risk of peripheral vascular complications, myocardial infarction and mortality . Acta Med Scand 1987; 221: 253—60.

20.

Willigendael EM , Teijink JA , Bartelink ML et al. Influence of smoking on incidence and prevalence of peripheral arterial disease. J Vasc Surg 2004; 40: 1158—65.

21.

Newman AB , Tyrrell KS , Kuller LH Mortality over four years in SHEP participants with a low ankle—arm index. J Am Geriatr Soc 1997; 45: 1472—78.

22.

Murabito JM , D'Agostino RB , Silbershatz H. , Wilson WF Intermittent claudication. A risk profile from The Framingham Heart Study. Circulation 1997; 96: 44—49.

23.

Hansson L. , Zanchetti A. , Carruthers SG et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351: 1755—62.

24.

Eagle KA , Guyton RA , Davidoff R. et al. ACC/AHH 2004 Guideline update for coronary artery bypass graft surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Commitee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery). American College of Cardiology 2004. URL: http://www.acc.org/clinical/guidelines/cabg/cabg.pdf .

25.

McIntosh A. , Hutchinson A. , Home PD , Brown F. , Bruce A. , Damerell A. Clinical guidelines and evidence review for Type 2 diabetes: management of blood glucose. The Royal College of General Practitioners Effective Clinical Practice Unit. Sheffield: SCHARR, University of Sheffield. 2005. URL: http://www.shef.ac.uk/guidelines/

26.

Patrono C. , Bachman F. , Baigent C. et al. Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European Society of Cardiology. Eur Heart J 2004; 25: 166—81.

27.

Fowkes FG , Price JF , Leng GC Targeting subclinical atherosclerosis. BMJ 1998; 316: 1764—70.

28.

Greenland P. , Abrams J. , Aurigemma GP et al. Prevention Conference V. Beyond secondary prevention: identifying the high-risk patient for primary prevention. Noninvasive tests of atherosclerotic burden. Circulation 2000; 101: e16—e22.

29.

Willigendael EM , Teijink JA , Bartelink ML et al. Combined training of GPs and practice-assistants on peripheral arterial disease: positive effects after six months. Fam Pract 2005; 22: 520—22.

30.

Fowkes FG , Housley E. , Macintyre CC , Prescott RJ , Ruckley CV Variability of ankle and brachial systolic pressures in the measurement of atherosclerotic peripheral arterial disease. J Epidemiol Community Health 1988; 42: 128—33.

31.

Stoffers HE , Kaiser V. , Kester AD , Schouten Hja , Knottnerus JA Peripheral arterial occlusive disease in general practice: the reproducibility of the ankle—arm systolic pressure ratio . Scand J Prim Health Care 1991; 9: 109—14.

A clinical prediction model for the presence of peripheral arterial disease — the benefit of screening individuals before initiation of measurement of the ankle—brachial index: an observational study

Abstract

Keywords

References